918628-81-6

Basic information

• Product Name: Propanedioic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]phenyl]-, 1,3-dimethyl ester
• CAS NO: 918628-81-6
• Molecular Formula: C16H20O6
• Molecular Weight: 308.331
• Mol File: 918628-81-6.mol

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]phenyl]-, 1,3-dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]phenyl]-, 1,3-dimethyl ester(918628-81-6)
• EPA Substance Registry System: Propanedioic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]phenyl]-, 1,3-dimethyl ester(918628-81-6)

Safety Data

• Hazardous Substances Data: 918628-81-6(Hazardous Substances Data)

Upstream product

• 586-75-4 4-chlorobenzoyl chloride 
• 59247-47-1 tert-butyl-4-bromobenzoate 
• 108-59-8 malonic acid dimethyl ester 

Downstream Products

• 918628-83-8 tert-butyl 4-[2-anilino-1-(anilinocarbonyl)-2-oxoethyl]benzoate 
• 918628-82-7 4-(2-[(3-chlorophenyl)amino]-1-{[(3-chlorophenyl)amino]carbonyl}-2-oxoethyl)benzoic acid 
• 936755-32-7 4-{[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoic acid 
• 936755-34-9 tert-butyl 4-{[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoate 
• 936755-33-8 tert-butyl 4-{2-[2-(2-methoxybenzoyl)hydrazin]-2-oxoethyl}benzoate 
• 936755-40-7 2-(4-tert-butoxycarbonyl-phenyl)-2-fluoro-malonic acid dimethyl ester 
• 732308-82-6 4-carboxymethyl-benzoic acid tert-butyl ester 
• 918628-84-9 4-[2-anilino-1-(anilinocarbonyl)-2-oxoethyl]benzoic acid 
• 918628-91-8 tert-butyl [2-({4-[2-anilino-1-(anilinocarbonyl)-1-methyl-2-oxoethyl]benzoyl}amino)-phenyl]carbamate 
• 918628-89-4 4-[2-anilino-1-(anilinocarbonyl)-1-hydroxy-2-oxoethyl]benzoic acid 

Relevant articles and documents

Inhibitors of Histone Deacetylase

The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS

The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differe

Design of novel histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors that target Class I and Class II HDACs are of synthetic and therapeutic interest and ongoing clinical studies indicate that they show great promise for the treatment of cancer. Moreover, ZolinzaR (vorinostat) was recently approved by the FDA for the treatment of the cutaneous manifestations of cutaneous T-cell lymphoma [Nat. Rev. Drug Disc. 2007, 6, 21]. As part of a broader effort to more fully explore the structure-activity relationships (SAR) of HDAC inhibitors, we sought to identify novel HDAC inhibitor structures through iterative design by utilizing low affinity ligands as synthetic starting points for SAR development. Novel and potent HDAC inhibitors have been identified using this approach and herein we report the optimization of the recognition elements of a novel series of malonyl-derived HDAC inhibitors.

FLUORINATED ARYLAMIDE DERIVATIVES

The present invention relates to a novel class of fluorinated arylamide derivatives. The instant compounds can be used to treat cancer. The fluorinated arylamide derivatives can also inhibit histone deacetylase and are suitable for use in selectively indu

MODIFIED MALONATE DERIVATIVES

The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.

HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS

The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal